Home
Antibodies and Antibody Drug Conjugates
9 April - 10 April 2018
Antibodies and Antibody Drug Conjugates

SAE Media Group is proud to present their 6th annual Antibodies and Antibody Drug Conjugates conference on the 9th-10th of April 2018. The Antibody-drug Conjugates market is expected to reach USD 30 Billion by 2023*. http://bit.ly/2hxLtOS

Antibodies and antibody drug conjugates (ADCs) have the potential to make a groundbreaking impact upon medicinal therapies, diagnostics and characterization of diseases. There is massive potential for ADCs to be used in the development of targeted solid tumour therapies, due to their ability to act as precisely and effectively on target antigens. 

Key topics that will be covered in the upcoming event include: fragment drug conjugates, ADC payloads, site-selective ADCs/ site-specific conjugation and the best linker and warhead combinations.

Hear from some of the best minds in the industry and partake in valuable discussion with key leaders within the field at this topical and timely event!

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Opening Remarks and Introductions

clock

9:10

Regulatory Strategy

Peter Bach

Peter Bach, Director, BioPharmaLogic Ltd.

  • Biology for the regulatory arguments
  • CMC for nonclinical development
  • Staging the test item supply to speed the development
  • clock

    10:00

    Taking the conjugate into the clinic

    Peter Bach

    Peter Bach, Director, BioPharmaLogic Ltd.

  • Geographical differences
  • Finding clinical leverage
  • Global option for FTIH
  • clock

    10:40

    Morning Coffee

    clock

    11:10

    Non-Clinical

    Peter Bach

    Peter Bach, Director, BioPharmaLogic Ltd.

  • Models
  • Service providers
  • Data interpretation
  • In vitro and in vivo safety assessments:

    - Literature Based Risk Assessment
    - Immunohistochemistry
    - CRO selection, Study design and CROs management

  • clock

    11:50

    Final considerations

    Peter Bach

    Peter Bach, Director, BioPharmaLogic Ltd.

  • Bioanalytical considerations
  • Agency interactions
  • The regulatory package
  • Outsourcing strategy – test item supply: matching nonclinical needs to speed the development
  • clock

    12:30

    Closing Remarks and End of Workshop

    clock

    13:30

    Registration & Coffee

    clock

    14:00

    Chairman's Opening Remarks

    clock

    14:10

    Antibody Structure and Function

  • Comparison of the five classes of antibodies and their determined binding specificity
  • Analysis of structure-function relationships for antibodies
  • Examination of C domains and how these mediate function
  • Antibody Bioinformatics and relationship to structure and function. INN naming system.
  • Mahendra  Deonarain

    Mahendra Deonarain, Chief Scientific and Operating Officer, Antikor Biopharma Ltd.

    Kerry Chester

    Kerry Chester, Professor, University College London

    clock

    14:50

    Antibody Biophysics

  • Biophysical characterization of antibodies and ADCs
  • Methods for the determination of antibody-antigen binding affinities
  • Where is the limit for analysis of antibodies using biophysical methods?
  • Mahendra  Deonarain

    Mahendra Deonarain, Chief Scientific and Operating Officer, Antikor Biopharma Ltd.

    Kerry Chester

    Kerry Chester, Professor, University College London

    clock

    15:30

    Afternoon Tea

    clock

    16:00

    Antibody Discovery

  • Analysis of sources (origins) of different antibodies
  • Strategies to accelerate antibody discovery
  • A look at current and emerging Antibody Discovery Technologies
  • Accelerating antibody discovery by protein expression
  • Mahendra  Deonarain

    Mahendra Deonarain, Chief Scientific and Operating Officer, Antikor Biopharma Ltd.

    Kerry Chester

    Kerry Chester, Professor, University College London

    clock

    16:40

    Antibody Conjugation

  • Methods of Antibody conjugation
  • Why is antibody-drug conjugation useful
  • The chemistry behind Antibody-Drug Conjugates
  • Mahendra  Deonarain

    Mahendra Deonarain, Chief Scientific and Operating Officer, Antikor Biopharma Ltd.

    Kerry Chester

    Kerry Chester, Professor, University College London

    clock

    17:20

    Closing Remarks

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Philip Howard, Chief Scientific Officer, Spirogen

    clock

    9:10

    Use of modelling and simulation to compare new generation HER-2 ADCs with Kadcyla™: a focus on PK and efficacy

    Alison Betts

    Alison Betts, ADC Scientist, Pfizer

  • Kadcyla is a HER-2 ADC approved in 2013 for patients with HER2+ metastatic breast cancer
  • Kadcyla is only efficacious in high HER2 tumors and patients are acquiring resistance
  • New generation HER-2 ADCs are being designed to overcome these limitations
  • PK/PD  methodologies for efficacy and safety differentiation will be presented
  • For PK predictions a mechanistic target mediated drug disposition model is proposed accounting for binding to shed HER-2 extracellular domain and variability across patients
  • clock

    9:50

    Application of a PK-PD Modeling & Simulation in Antibody-Drug Conjugate Development

    Aman Singh

    Aman Singh, PK-PD Scientist, Janssen

  • Preclinical to clinical translation
  • Bystander effect of ADCs
  • Binding site barrier of ADCs
  • Cell-level pharmacokinetics of ADCs
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    GlycoConnect™ and HydraSpace™ technologies for superior Antibody-Drug Conjugates

    Sander van Berkel

    Sander van Berkel, Director R&D Operations, Synaffix

  • Head-to-head comparison demonstrates superiority of Glycan-Conjugated ADCs (GlycoConnect™) versus mainstream technologies 
  • Readily adaptable HydraSpace™ enables highly hydrophobic payloads, dual warhead ADCs and further expands TI
  • Decomposition of Parameters Contributing to the Improved Therapeutic Index
  • GlycoConnect™ and HydraSpace™
  • clock

    11:40

    Antibody Targeted Amanitin Conjugates (ATACs) - Expanding the ADC landscape with a new payload targeting RNA Polymerase II

    Andreas Pahl

    Andreas Pahl, CSO, Heidelberg Pharma

  • Antigen-Targeted Amanitin-Conjugates (ATACs) represent a new class of ADCs using the payload Amanitin.
  • This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA polymerase II.
  • The technology platform includes Amanitin supply, site-specific conjugation, demonstrated safety profile and biomarker.
  • HDP-101 is the first ATAC directed against BCMA entering Phase I trials by the end of 2018
  • clock

    12:20

    Networking Lunch

    clock

    13:30

    Minor-Groove binding DNA-interactive molecules as ADC Payloads - the impact of sequence-selectivity and mono-alkylation versus cross-linking

    David E. Thurston

    David E. Thurston, Professor of Drug Discovery, King's College London

  • The impact of mono-alkylation versus intra- and interstrand cross-linking mechanisms of action on the in vitro and in vivo efficacy and toxicity of ADC payloads and ADCs.
  • Is there an opportunity to match the sequence-selectivity of DNA-interactive payloads to the genetic profiles of tumour types?
  • Is there an opportunity to improve the therapeutic window of ADCs by “tuning” the mechanism of action and sequence-selectivity of the payload?
  • clock

    14:10

    PBDs – update on an efficient and effective payload class

    Arnaud Tiberghien

    Arnaud Tiberghien, Scientist II, Chemistry, Spirogen

  • A potent and flexible class of ADC payloads and their industrial processing viability.
  • Whether or not PBDs make better payloads than others.
  • Comparison of PBD DNA crosslinkers and PBD DNA alkylators
  • New PBD payloads in developments. Consequences on mode of action, efficacy and tolerability
  • clock

    14:50

    Afternoon Tea

    clock

    15:20

    Novasep’s integrated solutions for ADCs

    Francois D'Hooge

    Francois D'Hooge, Head of Bioconjugation, Novasep S A S

  • Simplifying the supply chain through an integrated offer
  • Design considerations of a dedicated conjugation facility
  • Novasep’s strengths for ADCs: case studies
  • clock

    16:00

    Precision cancer therapy ADCs with novel target, antibody and cancer toxin technologies

    Robert Boyd

    Robert Boyd, UK Site Head and Scientific Director, Oxford BioTherapeutics

  • Selection of novel ADC cancer targets in the post-genomics era
  • Improved efficacy by optimizing targets to ADC technologies
  • Target Selection criteria - how to choose the best target for your specific need
  • clock

    16:40

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Mahendra  Deonarain

    Mahendra Deonarain, Chief Scientific and Operating Officer, Antikor Biopharma Ltd.

    clock

    9:10

    Antibody-Pyrrolobenzodiazepine Conjugates

    Philip Howard, Chief Scientific Officer, Spirogen

  • An overview of the PBB ADC Clinical landscape
  • Present 3 case studies on PBD-ADCs for haematological indications
  • Present 1 case study on a PBD-ADC in a solid indication
  • Case studies will include both clinical and preclinical data
  •  

    clock

    9:50

    Site-selective ADCs by disulfide bridging

    James Baker

    James Baker, Chemistry Lecturer, University College London

  • Site-selective ADCs offer the prospect of improved Therapeutic Indexes over traditional heterogeneous conjugation approaches, and are likely to form the basis of next generation ADCs.
  • Can achieve such site-selectivity by targeting the four interchain disulfide bonds (in IgG1s), using bridging reagents which reconnect the two cysteine residues.
  • We describe the development of Next Generation Maleimide reagents, and the related Pyridazinediones, as optimised platforms for ADCs constructed in this way.
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Antibody Fragment Drug Conjugates (FDCs): A tailored therapy for solid tumours

    Mahendra  Deonarain

    Mahendra Deonarain, Chief Scientific and Operating Officer, Antikor Biopharma Ltd.

  • Discovery of antibody fragments specifically designed for FDCs
  • Manufacture of FDCs and payload screening
  • In vivo pharmacokinetics and tumour cure efficacy in gastric cancer models
  • Rodent models for toxicology and tolerability
  • clock

    11:40

    Design principles for maximizing the drug delivery efficiency and therapeutic index of ADCs

    Robert Lyon

    Robert Lyon, Senior Director Protein Sciences, Seattle Genetics Ltd

  • The conjugation of drug-linkers to an antibody can result in increased nonspecific uptake and catabolism in healthy tissues
  • This phenomenon has two potential negative consequences—unintended delivery of the drug to non-target tissues, and diminished exposure of the tumor to the ADC
  • Careful design of the drug-linker can minimize this effect in preclinical models, with demonstrable decreases in drug concentrations in normal tissues paired with maximal delivery to the tumor
  • Toxicology and xenograft studies indicate that the optimized design both decreases off-target toxicity and improves antitumor activity, and we are currently planning to evaluate this design clinically with an anti-CD48 antibody for patients with multiple myeloma
     
  • clock

    12:20

    Networking Lunch

    clock

    13:30

    Highly Potent APIs (HPAPIs) in ADC projects

    Justin Mason-Home

    Justin Mason-Home, Director, HPAPI Project Services Limited

  • ADC Toxicants in the context of Pharma HPAPIs
  • Other ADC Component Hazards
  • Health and Safety Project Elements in Designing and Delivering HPAPI Projects
  • Risk Assessment, Risk Communication and Risk Management
  • clock

    14:10

    Anthracycline-based antibody drug conjugates with potent immune-stimulatory functions

    Roger Beerli

    Roger Beerli, CSO, NBE Therapeutics

  • Site-specific conjugation using sortase enzyme (SMAC™-Technology), yielding homogenous ADCs.
  • Highly potent payload, providing access to difficult-to-address targets.
  • Anthracycline-based payload with attractive IO properties.
  • clock

    14:50

    Afternoon Tea

    clock

    15:20

    The use of Nanobody formatting to improve immune-oncology therapeutics

    Carlo Boutton

    Carlo Boutton, Director of Technology, Ablynx

  • Small Nanobodies® with their modular design are a perfect starting point for generating multivalent and multispecific therapeutics for immune modulation.
  • The power of the platform and its flexibility to develop optimal drug formats will be demonstrated by a multivalent approach for an agonistic Nanobody against the co-stimulatory immune checkpoint receptor GITR and a multispecific T-cell recruitment format.
  • clock

    16:00

    The use of bispecific antibodies to modulate anti-tumour immune responses

    Delphine Buffet

    Delphine Buffet, Senior Research Associate, F-star

  • Bispecific antibodies: an attractive alternative to cancer treatments combinations
  • F-star’s approach to create bispecific mAb²
  • In vitro and in vivo efficacy of F-star bispecific antibodies targeting oncology pathways
  • clock

    16:40

    Chairman’s Closing Remarks and Close of Day Two

    Official Media Partner

    Supporters

    [SPEAKER INTERVIEW] - Robert Lyon, Senior Director Protein Sciences, Seattle Genetics

    Download

    [ATTENDEE LIST] - LIST OF COMPANIES & JOB TITLES

    Download

    [SPEAKER INTERVIEW] - Mahendra Deonarain, Chief Executive and Scientific Officer, Antikor Biopharma

    Download

    [2016 PRESENTATION] - SKAN

    Download

    [2016 PRESENTATION] - NBE Therapeutics

    Download

    [SPEAKER INTERVIEW] - Alison Betts, Associate Research Fellow, Pfizer

    Download

    Media Partners


    ADC Review

    Official Media Partner
    http://www.adcreview.com

    ADC Review / Journal of Antibody-drug Conjugates (ISSN: 2327-0152) is an international publication combining professional social media with an online-only, hybrid open-access, peer reviewed journal. The Journal aims to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. Key information includes peer-reviewed articles, news features, discussions, blogs, and a knowledge center offering the latest and most relevant information about Antibody Drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.

    Media Partners


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Pharma Marketing

    Supporters
    http://magazine.pharmamkt.net/



    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


    World Pharma News

    Supporters
    http://www.worldpharmanews.com/



    Journal for Clinical Studies – Your Resource for Multisite Studies & Emerging Markets

    Supporters
    http://www.JforCS.com

    Published bi-monthly.JCS is a unique journal, dedicated to providing information to the global pharmaceutical, biotechnology, medical devices and contract research organisations. JCS details practical and theoretical operational procedures, challenges, validatory and regulatory guidelines when conducting trials on a multisite basis and particularly within the emerging markets, naïve patient population, and remote access areas. JCS provides country by country objectives and uniquely brings you experiences in therapeutic areas of Liver diseases, kidney diseases, insect borne diseases, malnutrition and under nutrition. JCS is led by a strong editorial advisory board sourced out for their experiences; you will get the most practical insight for your global studies. JCS invites you to join us, write for us, feature your experiences with us, advertise your capabilities with us, and ask our advisory board for suggestions and guidelines. Let us make health care available to all.


    Medical Device Network

    Supporters
    http://www.medicaldevice-network.com/

    Medicaldevice-network.com is your one stop for information on the medical device industry, covering everything along the supply chain from biomaterials and materials solutions to electronics, packaging, motors and motion control, outsourcing and more. Through our international team of journalists, we cover diagnosis, prevention, monitoring, standards, treatment and technology – all you need as a professional in the medical industry to stay abreast of the latest developments in your field.


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.